Free tool
FAERS Monitor: Ciprodex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021537 or its brand name (Ciprodex, Ciprofloxacin, Dexamethasone). Reports on generic versions are filed under their own applications.
Reports
77
Serious
33
43% of reports
Hospitalization
21
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective11
- fatigue7
- product dose omission issue7
- dizziness5
- dyspnoea5
- headache5
- inappropriate schedule of product administration4
- nausea4
- neck pain4
- paraesthesia4
- pneumonia4
- product quality issue4
- product use in unapproved indication4
- pyrexia4
- vomiting4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 11 |
| 2024 | 11 |
| 2025 | 31 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,082 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neck painSignal | 4 | 19.6 | 7.5 | 53 |
| product quality issueSignal | 4 | 8.0 | 3.1 | 18 |
| paraesthesiaSignal | 4 | 6.9 | 2.7 | 15 |
| product dose omission issueSignal | 7 | 6.5 | 3.2 | 28 |
| inappropriate schedule of product administrationSignal | 4 | 6.1 | 2.3 | 12 |
| product use in unapproved indicationSignal | 4 | 4.4 | 1.7 | 7 |
| pneumoniaSignal | 4 | 3.4 | 1.3 | 5 |
| pyrexiaSignal | 4 | 3.2 | 1.2 | 4 |
| dizzinessSignal | 5 | 2.7 | 1.2 | 4 |
| fatigueSignal | 7 | 2.5 | 1.2 | 5 |
| dyspnoea | 5 | 2.4 | 1.0 | 3 |
| vomiting | 4 | 2.3 | 0.9 | 2 |
| drug ineffectiveSignal | 11 | 2.3 | 1.3 | 7 |
| headache | 5 | 2.2 | 0.9 | 2 |
| nausea | 4 | 1.4 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.